Related Experiment Video

Updated: May 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers

Taher Abu-Hejleh1, James J Mezhir, Michael J Goodheart

  • 1Department of Internal Medicine, Division of Hematology, Oncology, and Bone Marrow Transplantation, The University of Iowa Hospitals and Clinics, 200 Hawkins Dr., C32 GH, Iowa City, IA 52242-1081, USA. taher-hejleh@uiowa.edu

Current Oncology Reports
|April 26, 2012
PubMed

Insights

Bevacizumab, a cancer drug, can cause serious bowel perforation even without gastrointestinal tumors. Identifying at-risk patients remains a challenge for effective cancer treatment management.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Bevacizumab (Avastin) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF).
  • It inhibits angiogenesis, a key process in tumor growth and metastasis.
  • Its use has expanded for various cancers since FDA approval for metastatic colorectal cancer.

Purpose of the Study:

  • To review the anti-tumor activity of bevacizumab.
  • To highlight the serious side effect of bowel perforation associated with bevacizumab therapy.
  • To discuss the current understanding of risk factors and management strategies for bevacizumab-induced bowel perforation.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of bevacizumab's mechanism of action and its impact on angiogenesis.
  • Examination of reported cases of bevacizumab-associated bowel perforation.

Main Results:

  • Bevacizumab effectively disrupts cancer signaling and inhibits angiogenesis.
  • Serious side effects include spontaneous bowel perforation, even in patients without GI cancer involvement.
  • While some risk factors are known, precise identification of susceptible patients remains unclear.

Conclusions:

  • Bevacizumab is an effective anti-cancer agent but carries significant risks.
  • Bowel perforation is a critical complication requiring careful consideration.
  • Management strategies are guided by clinical presentation and patient-specific goals of care.

More Related Videos

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy04:05

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy

Published on: August 22, 2025

Related Concept Videos

Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Esophageal Perforation-I: Introduction01:22

Esophageal Perforation-I: Introduction

Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus.
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...